#AI #Biotechnology #Healthcare
www.forbes.com
How AI Is Transforming Patient Health At Genentech
How is AI transforming the world's original biotech company.
Genentech is an American biotechnology corporation headquartered in South San Francisco, California and celebrating its 50th anniversary this year.
#Biotechnology #FDAApproval #ClinicalTrials
www.nasdaq.com
Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal
(RTTNews) - This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes.
#Biotechnology #ArtificialIntelligence #Neurotechnology
nypost.com
Mad scientists to power AI data centers with living brain...
Scientists placed 200,000 living human brain cells on a microchip and taught it how to play a doomsday video game -- and are now using the dystopian tech to power AI data centers.
#HenriettaLacks #MedicalEthics #Biotechnology
edition.cnn.com
Novartis settles with Henrietta Lacks' estate over use of her 'stolen' cells to advance medicine
Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine.
#Biotechnology #Epilepsy #ConferenceCall
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET -
NEW YORK, Jan.
#Biotechnology #Epilepsy #ConferenceCall
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET -
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc.
#Biotechnology #AutoimmuneDiseases #ClinicalTrials
www.nasdaq.com
Jade Biosciences To Report Phase I Trial Of JADE101 In 1H2026
(RTTNews) - Jade Biosciences, Inc. (JBIO), a clinical-stage biotechnology company developing therapies for autoimmune diseases, announced its 2026 strategic priorities on Monday, including anticipated milestones before the 44th Annual J.
#Biotechnology #RNAMedicines #HealthcareInnovation
www.benzinga.com
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - WAVE Life Sciences (NASDAQ:WVE)
CAMBRIDGE, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.
#Biotechnology #Healthcare #InflammatoryDiseases
www.benzinga.com
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - Upstream Bio (NASDAQ:UPB)
WALTHAM, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.
S
#Sustainability #SupplyChain #Biotechnology
www.streetinsider.com
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility across the supply chain.
